Ponazuril Explained

Ponazuril (INN), sold by Merial, Inc.,[1] now part of Boehringer Ingelheim,[2] under the trade name Marquis® (15% w/w ponazuril), is a drug currently approved for the treatment of equine protozoal myeloencephalitis (EPM) in horses, caused by coccidia Sarcocystis neurona.[3] [4] Veterinarians have been preparing a formulary version of the medication for use in small animals such as cats, dogs, and rabbits against coccidia as an intestinal parasite. Coccidia treatment in small animals is far shorter than treatment for EPM.

See also

Notes and References

  1. Web site: Merial Acquires LEGEND® and MARQUIS® . Boehringer Ingelheim . 2018-04-30.
  2. Web site: Sanofi and Boehringer Ingelheim confirm Closing of business swap www.boehringer-ingelheim.com. boehringer-ingelheim.com. en. 2018-04-30.
  3. Web site: Marquis . Drugs.com.
  4. Mackay RJ, Tanhauser ST, Gillis KD, Mayhew IG, Kennedy TJ . Effect of intermittent oral administration of ponazuril on experimental Sarcocystis neurona infection of horses . American Journal of Veterinary Research . 69 . 3 . 396–402 . March 2008 . 18312139 . 10.2460/ajvr.69.3.396 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ponazuril".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.